Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506423 | 0.85 | NOS3 (0.43) | NOS3NOS2CRHR1MAPTFABP4 | |
| SCHEMBL18506606 | 0.82 | SMN1; SMN2 (0.42) | ADORA2APOLBMAPTKMT2AMEN1 | |
| SCHEMBL31574144 | 0.80 | NOTUM (0.38) | CRHR1POLBMAPTKMT2AS1PR4 | |
| SCHEMBL11703961 | 0.80 | MAPT (0.33) | ADORA2ACRHR1POLBMAPTKMT2A | |
| SCHEMBL17506403 | 0.80 | ADORA2A (0.44) | ADORA2APOLBMAPTKMT2AS1PR4 | |
| Hydrochloric Acid SCHEMBL9053873 | 0.80 | SMN1; SMN2 (0.41) | ADORA2APOLBMAPTKMT2AMEN1 | |
| SCHEMBL3713130 | 0.80 | NOTUM (0.38) | NOS3NOS2ADORA2APOLBMAPT | |
| SCHEMBL5728846 | 0.80 | NOTUM (0.38) | CRHR1POLBMAPTKMT2AS1PR4 | |
| SCHEMBL10272045 | 0.79 | NOS3 (0.39) | NOS3NOS2CRHR1FABP4KMT2A | |
| Hydrochloric Acid SCHEMBL17506448 | 0.78 | ADORA2A (0.43) | ADORA2APOLBMAPTKMT2AS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| CN-1158299-C | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, method fo r producing the same, medicaments containing these compounds and their use | ���ĵ�˹ҩ��¹�����˾ | 2004-07-21 | — | — | CN | disclosed |
| EP-1218401-B1 | 4-BENZYLAMINOQUINOLINE CONJUGATES WITH BILE ACID AND THEIR HETEROANALOGUES, METHODS FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE | AVENTIS PHARMA GMBH (DE) | 2004-06-16 | — | — | EP | disclosed |
| CN-1374968-A | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, method fo r producing the same, medicaments containing these compounds and their use | AVENTIS PHARMA PEUTSCHLAND GMB (DE) | 2002-10-16 | — | — | CN | disclosed |
| EP-1218401-A1 | 4-BENZYLAMINOQUINOLINE CONJUGATES WITH BILE ACID AND THEIR HETEROANALOGUES, METHODS FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| US-6339077-B1 | FOR PROPHYLAXIS OR OF GALLSTONES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-15 | — | — | US | disclosed |
| WO-2001021642-A1 | 4-BENZYLAMINOQUINOLINE CONJUGATES WITH BILE ACID AND THEIR HETEROANALOGUES, METHODS FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | NOS3 1997/4885NOS2 2684/4885ADORA2A 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.